Tumor Necrosis Factor-α Promotes the Expression of Osteoprotegerin in Rheumatoid Synovial Fibroblasts

Journal of Rheumatology

Volumn 31, Issue 3, 2004, Pages 426-435

  Kubota, Ayako ^a   Hasegawa, Kazuhisa ^a   Suguro, Toru ^a   Koshihara, Yasuko ^b  

^a TOHO UNIVERSITY   (Japan)

^b TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

Author keywords

Osteoprotegerin; RANKL; Rheumatoid arthritis; Synovial fibroblast; Tumor necrosis factor

Indexed keywords

FC RECEPTOR; HYBRID PROTEIN; HYMENIALDISINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSTEOPROTEGERIN; PROTEIN INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE DESTRUCTION; CELL CULTURE; CELL MATURATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; INFLAMMATION; NORTHERN BLOTTING; OSTEOCLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; SYNOVIOCYTE; SYNOVIUM; UPREGULATION;

ADULT; AGED; ANTIGENS, CD; ARTHRITIS, RHEUMATOID; CALCITRIOL; CARRIER PROTEINS; CELLS, CULTURED; FEMALE; FIBROBLASTS; GLYCOPROTEINS; HUMANS; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; OSTEOARTHRITIS, KNEE; OSTEOCLASTS; OSTEOPROTEGERIN; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; SYNOVIAL MEMBRANE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 1542724959     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Takayanagi H, Iizuka H, Juji T, et al. Involvement of receptor activator of nuclear factor κB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum 2000;43:259-69.
2. Shigeyama Y, Pap T, Kunzler P, Simmen BR, Gay RE, Gay S. Expression of osteoclast differentiation factor in rheumatoid arthritis. Arthritis Rheum 2000;43:2523-30.
3. Chu CQ, Field M, Feldmann M, Maini RN. Localization of tumor necrosis factor α in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum 1991;34:1125-32.
4. Deleuran BW, Chu CQ, Field M, et al. Localization of tumor necrosis factor receptors in the synovial tissue and cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum 1992;35:1170-8.
5. Manicourt DH, Poilvache P, Van Egeren A, Devogelaer JP, Lenz ME, Thonar EJ. Synovial fluid levels of tumor necrosis factor α and oncostatin M correlate with levels of markers of the degradation of crosslinked collagen and cartilage aggrecan in rheumatoid arthritis. Arthritis Rheum 2000;43:281-8.
6. Neidel J, Schulze M, Lindshau J. Association between degree of bone-erosion and synovial fluid-levels of tumor necrosis factor α in the knee-joints of patients with rheumatoid arthritis. Inflamm Res 1995;44:217-21.
7. Bathon JM, Martin RW, Fleishmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93.
8. Lipsky PE, van der Heijde DMFM, St. Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-602.
9. Vandenabeele P, Declercq W, Beyaert R, Fiers W. Two tumor necrosis factor receptors: structure and function. Trends Cell Biol 1995;5:392-9.
10. Abu-Amer Y, Erdmann J, Alexopoulou L, Kollias G, Ross FP, Teitelbaum SL. Tumor necrosis factor receptors type 1 and type 2 differentially regulate osteoclastogenesis. J Biol Chem 2000;275:27307-10.
11. Zhang YH, Heulsmann A, Tondravi MM, Mukherjee A, Abu-Amer Y. Tumor necrosis factor-α (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways. J Biol Chem 2001;276:563-8.
12. Mukherjee R, Singh S, Chaturvedi MM, Aggarwal BB. Evidence for synergistic role of two types of human tumor necrosis factor receptors for the ligand-dependent activation of the nuclear transcription factor NF-κB. J Interferon Cytokine Res 1998;18:117-23.
13. Brandstrom H, Bjorkman T, Ljunggren O. Regulation of osteoprotegerin secretion from primary cultures of human bone marrow stromal cells. Biochem Biophys Res Commun 2001;280:831-5.
14. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of the bone density. Cell 1997;89:309-19.
15. 2 in human bone marrow stroma cells. Biochem Biophys Res Commun 1998;247:338-41.
16. Sakata M, Shiba H, Komatsuzawa H, et al. Expression of osteoprotegerin (osteoclastogenesis inhibitory factor) in cultures of human dental mesenchymal cells and epithelial cells. J Bone Miner Res 1999;14:1486-91.
17. Vidal NOA, Sjogren K, Eriksson BI, Ljungger O, Ohlsson C. Osteoprotegerin mRNA is increased by interleukin-1α in the human osteosarcoma cell line MG-63 and in human osteoblast-like cells. Biochem Biophys Res Commun 1998;248:696-700.
18. Brandstrom H, Jonsson KB, Vidal O, Ljunghall S, Ohlsson C, Ljunggren O. Tumor necrosis factor-α and -β upregulate the levels of osteoprotegerin mRNA in human osteosarcoma MG-63 cells. Biochem Biophys Res Commun 1998;248:454-57.
19. Collin-Osdoby P, Rothe L, Anderson F, Nelson M, Maloney W, Osdoby P. Receptor activator of NF-κB and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines and role in human osteoclastogenesis. J Biol Chem 2001;276:20659-72.
20. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
21. Takayanagi H, Oda H, Yamamoto S, et al. A new mechanism of bone destruction in rheumatoid arthritis: synovial fibroblasts induce osteoclastogenesis. Biochem Biophys Res Commun 1997;240:279-86.
22. Takahashi N, Yamada, H, Yoshiki S, et al. Osteoclast-like cell formation and its regulation by osteotropic hormones in mouse bone marrow cultures. Endocrinology 1988;122:1373-82.
23. Kanehisa J, Yamanaka T, Doi S, et al. A band of F-actin containing podosomes is involved in bone resorption by osteoclasts. Bone 1990;1:287-93.
24. Davies JE, Shapiro G, Lowenberg BF. Osteoclastic resorption of calcium phosphate ceramic thin films. Cells and Materials 1993;3:245-56.
25. Auf'mkolk B, Hauschka PV, Schwartz ER. Characterization of human bone cells in culture. Calcif Tissue Int 1985;37:228-35.
26. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-9.
27. Burton KA. A study of the conditions and mechanism of the diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acid. J Biol Chem 1956;62:315-23.
28. 2 formation by the marine natural product hymenialdisine. J Pharmacol Exp Ther 1997;283:955-61.
29. Fujisawa K, Aono H, Hasunuma T, Yamamoto K, Mita S, Nishioka K. Activation of transcription factor NF-κB in human synovial cells in response to tumor necrosis factor α. Arthritis Rheum 1996;39:197-203.
30. Brennan FM, Chantry D, Jackson A, Maini RV, Feldmann M. Inhibitory effect of TNF-α antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989;2:244-7.
31. Morre BA, Aznavoorian S, Engler JA, Windsor LJ. Induction of collagenase-13 (MMP-13) in rheumatoid arthritis synovial fibroblasts. Biochim Biophy Acta 2000;1502:307-18.
32. Kassiotis G, Kollias G. Uncoupling the proinflammatory from the immunosuppressive properties of tumor necrosis factor (TNF) at the p55 TNF receptor level: implications for pathogenesis and therapy of autoimmune demyelination. J Exp Med 2001;193:427-34.
33. Burmester GR, Dimitriu-Bona A, Waters SJ, Winchester RJ. Identification of three major synovial lining cell populations by monoclonal antibodies directed to Ia antigens associated with monocytes/macrophages and fibroblasts. Scand J Immunol 1983;17:69-82.
34. Azuma Y, Kaji K, Katogi R, Takeshita S, Kudo A. Tumor necrosis factor-α induces differentiation of and bone resorption by osteoclasts. J Biol Chem 2000;275:4858-64.
35. Kobayashi K, Takahashi N, Jimi E, et al. Tumor necrosis factor-α stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med 2000;191:275-85.
36. Lam J, Takeshita S, Baker JE, Kanagawa O, Ross FP, Teitelbaum SL. TNF-α induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 2000;106:1481-8.
37. Kotake S, Udagawa N, Hakoda M, et al. Activated human T-cells directly induce osteoclastogenesis from human monocytes. Arthritis Rheum 2001;44:1003-12.
38. Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999;397:315-23.
39. Larry WM, Scott WB, Michael HS, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141-7.
40. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N Engl J Med 1997;337:1029-35.
41. Bolon B, Campagnuolo G, Hu Y-L, Duryea D, Feige U. Arthritis patterns in rats with adjuvant-induced arthritis define distinct mechanisms of joint protection for IL-1ra, sTNF-RI, and OPG [abstract]. Ann Rheum Dis 2000;59 Suppl 1:355.